为重度哮喘患者选择合适生物制剂
本文为Chest「How I Do It」系列关于重度哮喘的综述,讨论如何为重度哮喘患者选择合适生物制剂。目前已有六种生物制剂获批、涵盖四种靶向策略,且无头对头试验比较。作者基于2型气道炎症抑制的预期效果,结合临床试验和真实世界数据,通过一例重度未控制哮喘的四种变体提出决策框架。
要点
- 六种生物制剂涵盖抗IgE、抗IL-5/IL-5R、抗IL-4R、抗TSLP四种靶向策略。
- 选择应基于临床试验数据、生物标志物谱、安全性及合并症靶向机会。
- 可用血嗜酸性粒细胞和呼出气一氧化氮等生物标志物辅助决策。
核心结论
- 生物制剂选择应基于期望疗效的临床试验数据、患者生物标志物谱、安全性(如妊娠时)及一种生物制剂靶向两种合并症的机会。
- 使用血嗜酸性粒细胞和呼出气一氧化氮等全身及气道生物标志物及其他表型特征,作者提出一个便于治疗决策的框架。
研究设计与样本
- 本文为Chest「How I Do It」系列关于重度哮喘的综述,基于抑制2型气道炎症不同方面的预期效果,并尽可能由临床试验和真实世界数据支持。
- 通过一例重度未控制哮喘的四种变体来展开概念与考虑。
主要发现
- 目前已有六种生物制剂获批用于重度哮喘,涵盖四种不同靶向策略:抗IgE(奥马珠单抗)、抗IL-5及抗IL-5受体(美泊利珠单抗、瑞利珠单抗、贝那利珠单抗)、抗IL-4受体(度普利尤单抗)、抗胸腺基质淋巴细胞生成素(tezepelumab)。
- 尚无头对头试验比较生物制剂。
关键数值与推荐
- 六种获批生物制剂涵盖四种靶向策略:抗IgE、抗IL-5/IL-5R、抗IL-4R、抗TSLP。
- 使用血嗜酸性粒细胞和呼出气一氧化氮(Feno)作为全身及气道生物标志物辅助决策。
临床怎么用
- 根据期望疗效的临床试验数据、患者生物标志物谱、安全性(如妊娠时)及一种生物制剂靶向两种合并症的机会选择生物制剂。
- 讨论妊娠相关、生物标志物相关、合并症相关及糖皮质激素依赖相关的考虑。
- 讨论何时、为何及如何从一种生物制剂转换为另一种。
局限性
- 尚无头对头试验比较生物制剂。
- 亟需事后研究和新的比较研究来检验该框架并确定其能否做出其他临床有用预测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this installment of the How I Do It series on severe asthma, we tackle the clinical conundrum of choosing the right biologic for the right patient with severe asthma. With six biologics now approved for use in this area comprising four different targeting strategies (anti-Ig E: omalizumab; anti-IL-5 and anti-IL-5-receptor: mepolizumab, reslizumab, and benralizumab; anti-IL-4-receptor: dupilumab; anti-thymic stromal lymphopoietin: tezepelumab), this question is increasingly complex. Recognizing that no head-to-head trial has compared biologics, we based our review on the expected effects of inhibiting different aspects of type 2 airway inflammation, supported whenever possible by clinical trial and real-world data. We use four variations of a case of severe uncontrolled asthma to develop concepts and considerations introduced in the previous installment ("Workup of Severe Asthma") and discuss pregnancy-related, biomarker-related, comorbidity-related, and corticosteroid dependency-related considerations when choosing a biologic. The related questions of deciding when, why, and how to switch from one biologic to another also are discussed. Overall, we consider that the choice of biologics should be based on the available clinical trial data for the desired efficacy outcomes, the biomarker profile of the patient, safety profiles (eg, when pregnancy is considered), and opportunities to target two comorbidities with one biologic. Using systemic and airway biomarkers (blood eosinophils and exhaled nitric oxide [Feno]) and other phenotypic characteristics, we suggest a framework to facilitate therapeutic decision-making. Post hoc studies and new comparative studies are needed urgently to test this framework and to determine whether it allows us to make other clinically useful predictions.
引用
- Couillard S, Jackson DJ, Pavord ID, et al. Choosing the Right Biologic for the Right Patient With Severe Asthma. Chest. 2024. PMID: 39245321. doi:10.1016/j.chest.2024.08.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。